T1	p 42 48	humans
T2	p 138 149	torcetrapib
T3	p 335 357	healthy young subjects
T4	p 443 461	of 8 subjects each
T5	p 634 641	treated
T6	p 651 661	completing
T7	p 1598 1606	subjects
T8	i 71 88	cholesteryl ester
T9	i 98 105	protein
T10	i 188 205	cholesteryl ester
T11	i 215 222	protein
T12	i 230 255	) inhibitor torcetrapib (
T13	i 481 513	placebo ( n=2 ) or torcetrapib (
T14	i 592 603	Torcetrapib
T15	i 1187 1205	Apolipoprotein A-I
T16	i 1307 1320	. Cholesteryl
T17	o 14 38	high-density lipoprotein
T18	o 223 224	(
T19	o 272 331	raise high-density lipoprotein cholesterol ( HDL-C ) levels
T20	o 592 603	Torcetrapib
T21	o 613 622	tolerated
T22	o 693 727	plasma drug levels with inhibition
T23	o 901 918	. CETP inhibition
T24	o 963 985	elevations of HDL-C of
T25	o 1001 1025	Total plasma cholesterol
T26	o 1081 1089	nonHDL-C
T27	o 1129 1164	low-density lipoprotein cholesterol
T28	o 1202 1205	A-I
T29	o 1210 1211	E
T30	o 1261 1265	apoB
T31	o 1345 1371	and triglyceride increased
T32	o 1379 1401	nonHDL plasma fraction
T33	o 1551 1562	work serves